OLD Second National Bank of Aurora trimmed its position in Johnson & Johnson (NYSE:JNJ – Free Report) by 2.2% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 33,130 shares of the company’s stock after selling 735 shares during the period. Johnson & Johnson makes up about 1.6% of OLD Second National Bank of Aurora’s portfolio, making the stock its 13th largest holding. OLD Second National Bank of Aurora’s holdings in Johnson & Johnson were worth $5,484,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Peak Asset Management LLC grew its position in Johnson & Johnson by 9.3% during the 1st quarter. Peak Asset Management LLC now owns 13,789 shares of the company’s stock worth $2,137,000 after purchasing an additional 1,171 shares in the last quarter. Nisa Investment Advisors LLC lifted its stake in shares of Johnson & Johnson by 0.9% in the first quarter. Nisa Investment Advisors LLC now owns 748,842 shares of the company’s stock valued at $116,071,000 after buying an additional 6,836 shares during the period. Vaughan Nelson Investment Management L.P. raised its stake in shares of Johnson & Johnson by 21.8% in the 1st quarter. Vaughan Nelson Investment Management L.P. now owns 903,546 shares of the company’s stock valued at $140,050,000 after buying an additional 161,687 shares in the last quarter. Tekla Capital Management LLC boosted its stake in Johnson & Johnson by 12.8% in the 1st quarter. Tekla Capital Management LLC now owns 721,779 shares of the company’s stock valued at $111,876,000 after buying an additional 82,100 shares in the last quarter. Finally, Franklin Street Advisors Inc. NC grew its stake in Johnson & Johnson by 0.7% during the second quarter. Franklin Street Advisors Inc. NC now owns 80,179 shares of the company’s stock worth $13,271,000 after buying an additional 562 shares during the last quarter. 68.40% of the stock is owned by institutional investors.
Johnson & Johnson Stock Performance
Shares of JNJ opened at $156.85 on Monday. The company has a current ratio of 1.12, a quick ratio of 0.88 and a debt-to-equity ratio of 0.44. The firm’s fifty day simple moving average is $163.10 and its two-hundred day simple moving average is $162.57. Johnson & Johnson has a 12 month low of $150.11 and a 12 month high of $181.04. The stock has a market capitalization of $407.65 billion, a P/E ratio of 31.75, a price-to-earnings-growth ratio of 3.21 and a beta of 0.55.
Johnson & Johnson Announces Dividend
The business also recently disclosed a quarterly dividend, which was paid on Thursday, September 7th. Stockholders of record on Monday, August 28th were given a dividend of $1.19 per share. The ex-dividend date was Friday, August 25th. This represents a $4.76 dividend on an annualized basis and a dividend yield of 3.03%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 96.36%.
Wall Street Analyst Weigh In
Several research analysts have issued reports on the company. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $215.00 price objective on shares of Johnson & Johnson in a report on Monday, October 9th. TheStreet upgraded Johnson & Johnson from a “c+” rating to a “b+” rating in a report on Monday, August 21st. Barclays raised their target price on Johnson & Johnson from $158.00 to $162.00 and gave the stock an “equal weight” rating in a report on Thursday. Stifel Nicolaus increased their price target on shares of Johnson & Johnson from $165.00 to $175.00 in a research report on Friday, July 21st. Finally, Wells Fargo & Company decreased their price objective on shares of Johnson & Johnson from $195.00 to $186.00 and set an “overweight” rating for the company in a report on Thursday, August 31st. Eight analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $171.00.
Read Our Latest Stock Report on Johnson & Johnson
Insider Buying and Selling at Johnson & Johnson
In related news, insider William Hait sold 14,698 shares of the company’s stock in a transaction dated Wednesday, July 26th. The shares were sold at an average price of $172.00, for a total value of $2,528,056.00. Following the sale, the insider now owns 87,747 shares in the company, valued at approximately $15,092,484. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In other Johnson & Johnson news, VP Peter Fasolo sold 20,000 shares of the business’s stock in a transaction on Tuesday, July 25th. The shares were sold at an average price of $170.32, for a total transaction of $3,406,400.00. Following the sale, the vice president now owns 102,696 shares of the company’s stock, valued at approximately $17,491,182.72. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider William Hait sold 14,698 shares of Johnson & Johnson stock in a transaction on Wednesday, July 26th. The shares were sold at an average price of $172.00, for a total value of $2,528,056.00. Following the completion of the transaction, the insider now owns 87,747 shares of the company’s stock, valued at $15,092,484. The disclosure for this sale can be found here. Insiders own 0.20% of the company’s stock.
Johnson & Johnson Profile
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.
Featured Articles
- Five stocks we like better than Johnson & Johnson
- What Are Defense Contractor Stocks? How to Invest in Defense
- MarketBeat Week in Review – 10/9 – 10/13
- Insider Trades May Not Tell You What You Think
- What BlackRock’s Earnings Tell You About The Stock Market Tide
- How to Know Which Cryptocurrency to Buy: A Guide for Investors
- Sociedad Quimica y Minera de Chile Well Positioned Lithium Stock
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
